Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review.
We performed a systematic review of changes in fecal and colon microbiomes of patients with inflammatory bowel diseases (IBD) receiving treatment with monoclonal antibodies against tumor necrosis factor (TNF), integrins, or cytokines. We explored associations among microbiome composition and functions (at baseline and throughout the treatment) and therapy-related outcomes to determine whether colon or fecal microbiomes might be used as biomarkers of response to therapy. We searched the PubMed, Web of Science and Science Direct databases through February 2019 for studies of associations among the microbiomes of fecal or colon samples, biologic therapies, and inflammatory bowel diseases. We used the critical appraisal skills program checklist to assess the quality of the study methods. From the 787 citations identified, 10 studies met the inclusion criteria. Changes in microbiomes of fecal or colon samples following treatment did not differ significantly among biologic agents; all produced decreases in relative abundances of Escherichia and Enterococcus and increases in genera that produce short-chain fatty acids. Fecal or colon microbiomes of patients who responded to therapy with antagonists of TNF or interleukins had higher alpha-diversity and increased relative abundances of different genera (Faecalibacterium, Roseburia, or Clostridium) from the Clostridiales order, either at baseline or during follow up. Patients in remission after treatment with antibodies against integrins had decreased abundances of Roseburia. In a systematic review of 10 studies, we found evidence for consistent changes in microbiomes of fecal and colon samples from patients with IBD who responded to treatment with biologic agents. Prospective studies are needed to determine what changes are significantly associated with treatment, whether these changes are causes or effects of response, or whether the composition of the intestinal microbiome can be used to select treatments for patients with IBD.